Catherine A. Fine, MS, CGC

An early-stage company combining a concierge-style care model, with a suite of individualized cutting-edge technologies and therapeutics, to help oncology patients with any cancer type achieve long-term, exceptional outcomes, by activating and harnessing anti-tumor immunity, and creating bespoke cancer vaccines and personalized cell therapy.

Founder of a genetics and genomics consulting and advisory practice which collaborates with and provides oncology subject matter expertise to industry partners, healthcare systems and providers, advocacy partners, and governmental groups. Backed by 20+ years of industry, clinical and academic experience Partnerships primarily focus on enhancing business practices and clinical programs, supporting research and commercial strategy, providing direct patient care, and improving patient quality of care.

Navio is a pre-Series A, technology company developing a digital health patient-centric platform to support patients and partners in longitudinal observation and data collection in clinical, research, and commercial settings. Recruited as employee number seven to serve as the clinical expert, working in collaboration with operations, design, engineering, and product management to accelerate Navio’s growth, impact, and competitive edge.

ABGC is a not-for-profit organization incorporated in 1993 for the purpose of certifying and recertifying genetic counselors. It is led by an elected Board of Directors comprised of certified genetic counselors and a public advisor, and is made up of over 90 ABGC Diplomates volunteering as committee members in different capacities.

Genome Medical is a digital health company and specialty medical group focused on genetics and genomics and making personalized medicine accessible to everyone. Recruited to Genome Medical as employee number 5 to create, develop, and lead the clinical cancer services division.

An academic career path of clinical service, research, teaching, and supervision, based primarily in genetics, genomics, and hereditary predispositions to cancer.